Diphtheria Scare in Edo State: Calls for School Closure Amid Rising Cases

In a major step toward health independence, a Nigerian company, Codix Bio Limited, is set to begin the local production of HIV and malaria test kits. This initiative follows significant funding cuts from the United States government, which had previously provided substantial financial support for Nigeria’s health programs through USAID and other agencies.
In 2024 alone, the U.S. contributed over $740 million to Nigeria’s health sector, supporting critical programmes for HIV treatment, malaria prevention, and immunization. However, a recent shift in U.S. foreign aid policy has led to a suspension of new funding, raising serious concerns about the sustainability of these essential services.
To bridge the gap, Codix Bio has partnered with South Korean medical diagnostics firm SD Biosensor, with technical support from the World Health Organization (WHO). The new facility, located near Lagos, is expected to produce up to 147 million test kits annually, a capacity large enough to meet Nigeria’s domestic demand and extend supply to neighbouring African countries.
Nigeria accounts for a significant portion of global malaria cases and ranks fourth globally in terms of HIV burden. The U.S. aid cut could have crippled diagnostic and treatment services, but Codix Bio’s move offers a local solution that may prevent a healthcare crisis.
In response to the funding cuts, the Nigerian government has also approved over ₦200 billion for HIV, tuberculosis, malaria, and immunization programs, showing a renewed commitment to self-reliance in healthcare.
This initiative not only ensures continuity in testing and treatment but also boosts local manufacturing, creates jobs, and strengthens the country’s health infrastructure. Codix Bio’s effort marks a shift from foreign dependency to national self-sufficiency—a necessary evolution for Nigeria’s long-term public health security.
Comments